Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The global sedation in ICU setting market size reached a value of around USD 3.34 Billion in 2025. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2026-2035 to attain a value of USD 5.76 Billion by 2035.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
5.6%
Value in USD Billion
2026-2035
*this image is indicative*
A state of serenity, relaxation, or sleepiness brought on by medicines is referred to as sedation. During medical or surgical procedures, sedation may be used to help people cope with severely stressful situations or to reduce anxiety. In the ICU setting, sedative drugs are frequently used primarily to alleviate agitation and anxiety, which can be brought on by a variety of different diseases.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The EMR’s report titled “Sedation in ICU Setting Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Region
Based on drug class, the market was dominated by propofol in the historical period. During the forecast period, the segment is expected to dominate the sedation in ICU setting market. This occurs as a result of propofol's rapid uptake as a painkiller and agitation suppressant in mechanical breathing. In the upcoming years, this will help propofol's market expansion, along with the introduction of generic products.
In order to sedate patients in the ICU, propofol is frequently given as a continuous intravenous infusion. Propofol has special qualities that allow it to penetrate the blood-brain barrier quickly, which causes sedation to start working quickly. Additionally, coronavirus (COVID-19) patients in the intensive care unit (ICU) who require mechanical breathing may be sedated with propofol.
It is anticipated that North America will dominate the global sedation in ICU setting market. This is because of the increasing older population with comorbid illnesses and increasing number of beds for critical care in developed countries like Canada and the United States. The region's expansion is also being fuelled by the rise in infectious disorders including sepsis and respiratory conditions that require ICU hospitalisation.
Growing hospital ICUs, expanding healthcare infrastructure, and an increase in ICU admissions are some of the key drivers of the global sedation in ICU setting market in developing nations in the Asia Pacific and Latin American regions.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global sedation in ICU setting market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
Medtronic plc, founded in 1949 is a leading manufacturer of medical equipment and treatments, including pacemakers, insulin pumps, and treatments for diabetes. It is best recognised for its ground-breaking cardiac devices, including pacemakers that are battery-operated and small. However, it has also put cutting-edge technologies into the market.
AstraZeneca plc, a holding company with its headquarters in the United Kingdom is involved in the creation, production, and research of pharmaceutical goods. To treat diseases in the cancer, cardiovascular, infection, neurological, respiratory, gastrointestinal, and inflammatory domains, the business develops, produces, and sells pharmaceutical and biotechnology products.
GlaxoSmithKline plc, one of the biggest research-based pharmaceutical firms in the world is headquartered in England and produces, promotes, and distributes products for human health. For the purpose of preventing and treating disease, it creates novel vaccinations and specialised medications.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other market players include Mylan N.V., Teva Pharmaceutical Industries Ltd., and B. Braun Medical, among others.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2025, the global market for sedation in ICU setting attained a value of nearly USD 3.34 Billion.
The market for sedation in ICU setting is projected to grow at a CAGR of 5.60% during the forecast period of 2026-2035.
The sedation in ICU setting market is estimated to witness a healthy growth in the forecast period of 2026-2035 to reach USD 5.76 Billion by 2035.
The major drivers of the market include the increasing patient pool, increasing investment towards improvement of healthcare facilities, rise in disposable income of people, rising number of critical care beds in the developed nations, growing number of hospitals ICUs and rising ICU admissions.
A rise in geriatric population and increasing cases of comorbid diseases are the key trends propelling the growth of the market.
The major regions in the sedation in ICU setting market are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The major players in the market include Medtronic plc, AstraZeneca plc, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., and B. Braun Medical, among others.
The benzodiazepines midazolam and lorazepam (and to a lesser extent, diazepam), the short-acting intravenous anaesthetic propofol, and dexmedetomidine are sedatives that are frequently used in the ICU. The sedative properties of the opioid remifentanil led to its usage as a single agent.
Some patients require long-term sedation, perhaps for weeks. The anaesthetic will often be turned off once the issue for which they were admitted to the ICU has been resolved so they can be evaluated. The breathing tube may be removed if they are performing well.
In order to maximise ventilator synchronisation and lessen any discomfort associated with critical illness, patients who were mechanically ventilated in the ICU were traditionally kept thoroughly sedated with ongoing depressive infusions.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share